Mu-opioid receptor antagonists have been claimed to produce inhibitory effects on experimentally induced itch in normal subjects 1) and pruritus in patients with dermatoses and visceral diseases. [2][3][4] In animal experiments, mu-opioid receptor antagonists suppress itch-related behaviors in several kinds of itch models. [5][6][7][8][9][10] The mu-opioid receptor antagonist naltrexone suppresses itch-related behaviors without effects on the increased activity of primary afferents, suggesting that it inhibits itch through central action.
6)There are at least two possible sites of pruritogenic action of opioids, the spinal dorsal horn and the lower brainstem. An intradermal injection of histamine induces hyperalgesia (enhanced prickling pain) and hyperknesis (enhanced pricking-evoked itch), and intradermal pretreatment with the local anesthetic chloroprocaine produces the inhibition of pain and the enhancement of itch.11) In contrast, itch sensation is generally reduced by pain produced by scratching. Therefore, it was suggested that itch produced by intrathecal and epidural injection of mu-opioid receptor agonists in humans is due to the inhibition of pain input by opioids in the dorsal horn.
12)Regarding the lower brainstem, injections of mu-opioid receptor agonists into the cisterna magna and medullary dorsal horn evoked facial scratching in animals. [13][14][15][16] Since naltrexone inhibits scratching, but not Fos expression in the spinal dorsal horn, evoked by an intradermal injection of serotonin, it is suggested that mu-opioid receptor in the brain, rather than the spinal dorsal horn, is involved in itch.17) Thus, the present study was conducted to determine whether cutaneous itch involves mu-opioid receptors in either of the spinal dorsal horn or lower brainstem or in both regions.Serotonin is a potent pruritogen in mice. 18) Scratching behavior and increase in cutaneous nerve firing following an intradermal injection of serotonin are similar to each other in dose-response relationship and time-course, suggesting the peripheral pruritogenic action of serotonin.18) An intradermal injection of serotonin causes scratching through 5-HT 2 serotonin receptor in the skin.10) An injection of serotonin into the hind paw elicits biting and licking of the treated paw, and an injection of dilute formalin licking alone.5) Systemic injections of the opioid antagonist naloxone and the 5-HT 1/2 serotonin receptor antagonist methysergide suppress biting, but not licking, induced by serotonin.5) These findings suggest that serotonin-induced biting behavior is an itch-related response. Thus, in the present experiments, we compared the effects of intrathecal injection via a lumbar puncture and intracisternal injection of naloxone on serotonin-induced biting of the hind paw. We also tested whether intracisternal injection of naloxone would affect serotonin-induced scratching of the rostral back, another itch-related response.
MATERIALS AND METHODS
AnimalsMale ICR mice (Japan SLC, Shizuoka) of 5-7 weeks of age were used. The...